Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Neoplasms 5Prostatic Neoplasms 3Solid Tumors 2Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Cancers 1Skin Diseases 1Prostatic Neoplasms, Castration-Resistant 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

pembrolizumab 75Carboplatin 46Paclitaxel 44130-nm albumin-bound paclitaxel 35Gemcitabine 34Cyclophosphamide 23Capecitabine 22Nivolumab 21Albumin-Bound Paclitaxel 21atezolizumab 20sacituzumab govitecan 14spartalizumab 13Doxorubicin 11olaparib 9Cisplatin 9Bevacizumab 9eribulin 8fludarabine 7durvalumab 7avelumab 7Injections 7Fulvestrant 7Fluorouracil 7Vinorelbine 6Leucovorin 6Docetaxel 6iniparib 5budigalimab 5Ipilimumab 5Epirubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Triple Negative Breast Neoplasms × ipatasertib × Clear all
NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Hoffmann-La Roche

Phase 3 Completed
242 enrolled 12 charts
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡